(Q44251158)

English

A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma (English)

1 reference

Europe PubMed Central

1 December 2017

1 reference

based on heuristic

inferred from title

author name string

F M Honrubia

1

1 reference

Europe PubMed Central

1 December 2017

L I Larsson

2

1 reference

Europe PubMed Central

1 December 2017

D Spiegel

3

1 reference

Europe PubMed Central

1 December 2017

European latanoprost study group

4

1 reference

Europe PubMed Central

1 December 2017

publication date

1 December 2002

1 reference

Europe PubMed Central

1 December 2017

Acta Ophthalmologica

1 reference

Europe PubMed Central

1 December 2017

80

1 reference

Europe PubMed Central

1 December 2017

6

1 reference

Europe PubMed Central

1 December 2017

635-641

1 reference

Europe PubMed Central

1 December 2017

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

The iris after prostanoid treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

21 January 2018

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

7 January 2021

based on heuristic

inferred from DOI database lookup

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800615.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0420.2002.800615.X

1 reference

Europe PubMed Central

1 December 2017

release_cmizrkydprcpdplc2chg7464ty

1 reference

https://api.fatcat.wiki/v0/release/cmizrkydprcpdplc2chg7464ty

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44251158&oldid=2108913700"